Key facts
- It has raised $12.5M; the latest was Angel (individual) in Dec 2024.
- Notable investors include PV Capital Management, Angel Physicians Fund, Catalyst Health Ventures, Excelestar Ventures, Hub Angels Investment Group — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for EyeCool Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for EyeCool Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EyeCool Therapeutics
Developer of a novel device-based technology designed to focus on developing innovative treatments for Chronic Ocular Surface Pain (COSP). The company delivers a targeted, precise dose of thermal energy to transform the experience of COSP patients and the product workflow integrates into current clinical workflows, ensuring efficient and effective patient care, enabling the healthcare industry to provide fast and lasting relief for patients suffering from this condition.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 10
- Website
- eyecooltx.com/
- Ownership
- Privately Held (backing)
EyeCool Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EyeCool Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EyeCool Therapeutics in its N-PORT filings yet. We sweep new filings monthly.